Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Cancer Patients With Major Depressive Disorder
NCT04593563Phase 2Unknown
- Sponsor
- Maryland Oncology Hematology
- Start
- Sep 2020
- Primary completion
- Oct 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Maryland Oncology Hematology. Primary endpoints: Montgomery-Åsberg Depression Rating Scale at 8 weeks, Quick Inventory of Depressive Symptomatology Self reported at 8 weeks and 13 more. Status: unknown.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04593563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593563.